MSK Cancer Center research advances include proton therapy for leptomeningeal metastasis and evaluating large language models for cancer pain summary.
Key Details
- 1Proton therapy controls leptomeningeal metastasis, with patients living over twice as long versus conventional radiation.
- 2Randomized phase 2 trial: proton craniospinal therapy offers stability >3x longer for LM compared to standard radiation.
- 3Study funded by PCORI explores LLM-based PainReporter model to summarize cancer patient pain experiences from narrative notes.
- 4Research on tumor genetics and location finds SMAD4 reactivation suppresses liver metastases but increases lung metastases.
- 5Regulatory T cells, via enkephalin, regulate pain/inflammation in skin neuronal circuits.
Why It Matters
Advances in radiotherapeutic options like proton therapy improve outcomes in difficult cancer metastasis scenarios. Testing LLMs for summarising patient pain could impact clinical workflow, interpretation, and the integration of AI into patient care.
Source
EurekAlert
Related News
•EurekAlert
Mass General Brigham Spins Off AIwithCare to Transform Clinical Trial Screening
Mass General Brigham has spun out AIwithCare, a company commercializing RECTIFIER, an AI tool that automates and enhances clinical trial patient screening using EHR data.
•EurekAlert
AI-Driven CT Imaging Predicts Cardiac Events in Large UK Cohort
An AI tool analyzing CCTA images can predict future cardiovascular events and death in patients with suspected stable coronary artery disease.
•EurekAlert
AI Tool from UCLA Targets Undiagnosed Alzheimer's and Diagnostic Disparity
UCLA researchers developed an AI model using EHR data to better detect undiagnosed Alzheimer's disease, especially in underrepresented groups.